Oyster Point Pharma to Present New Clinical Data at ASCRS 2022

Oyster Point Pharma announced the presentation of data analyses at the American Society of Cataract and Refractive Surgery (ASCRS), being held on April 22-26. The company-sponsored clinical trials that will be presented highlight the recently approved Tyrvaya (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease and its potential benefits to broader patient populations.

Details for the Oyster Point New Data Presentations are below:

Details for the Oyster Point New Data Presentations are below:

Title: Fellow Eye Outcomes with Pharmacologic Neuro-Activator Nasal Spray in Dry Eye Disease: ONSET-1 & ONSET-2 Studies
Authors: James Katz, MD, Mandy Hemphill, PhD, Andrea Gibson, PhD, Alan Kabat, OD, Laura Hendrix, MS
Date/Time: Friday, April 22, 2022
Location: Washington, DC – ASCRS Education Hub

Title: Symptom Score in Dry Eye Patients Exposed to Controlled Adverse Environment Following Treatment with OC-01/OC-02: Onset-1 and Pearl
Authors: Mark Milner, MD, Andrea Gibson, PhD, Puja Shah, OD, Laura Hendrix, MS
Date/Time: Friday, April 22, 2022
Location: ASC Washington, DC – ASCRS Education Hub